Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
Multi-platform proteomic analysis of Alzheimer's disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome.
复制标题
DOI:
10.1186/s13195-022-01113-5
复制
发表时间:
2022-11-17
影响因子:
9
通讯作者:
Johnson, Erik C. B.
中科院分区:
文献类型:
--
作者:
Dammer, Eric B.;Ping, Lingyan;Duong, Duc M.;Modeste, Erica S.;Seyfried, Nicholas T.;Lah, James J.;Levey, Allan, I;Johnson, Erik C. B.
Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer’s disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer’s disease cerebrospinal fluid (CSF) and plasma from the same subjects (n=18 control, n=18 AD) using three different proteomic platforms—SomaLogic SomaScan, Olink proximity extension assay, and tandem mass tag-based mass spectrometry—to assess which protein markers in these two biofluids may serve as reliable biomarkers of AD pathophysiology observed from unbiased brain proteomics studies. Median correlation of overlapping protein measurements across platforms in CSF (r~0.7) and plasma (r~0.6) was good, with more variability in plasma. The SomaScan technology provided the most measurements in plasma. Surprisingly, many proteins altered in AD CSF were found to be altered in the opposite direction in plasma, including important members of AD brain co-expression modules. An exception was SMOC1, a key member of the brain matrisome module associated with amyloid-β deposition in AD, which was found to be elevated in both CSF and plasma. Protein co-expression analysis on greater than 7000 protein measurements in CSF and 9500 protein measurements in plasma across all proteomic platforms revealed strong changes in modules related to autophagy, ubiquitination, and sugar metabolism in CSF, and endocytosis and the matrisome in plasma. Cross-platform and cross-biofluid proteomics represents a promising approach for AD biomarker development. The online version contains supplementary material available at 10.1186/s13195-022-01113-5.
登录
查看更多内容
影响因子:
3.7
作者:
Gold L;Ayers D;Bertino J;Bock C;Bock A;Brody EN;Carter J;Dalby AB;Eaton BE;Fitzwater T;Flather D;Forbes A;Foreman T;Fowler C;Gawande B;Goss M;Gunn M;Gupta S;Halladay D;Heil J;Heilig J;Hicke B;Husar G;Janjic N;Jarvis T;Jennings S;Katilius E;Keeney TR;Kim N;Koch TH;Kraemer S;Kroiss L;Le N;Levine D;Lindsey W;Lollo B;Mayfield W;Mehan M;Mehler R;Nelson SK;Nelson M;Nieuwlandt D;Nikrad M;Ochsner U;Ostroff RM;Otis M;Parker T;Pietrasiewicz S;Resnicow DI;Rohloff J;Sanders G;Sattin S;Schneider D;Singer B;Stanton M;Sterkel A;Stewart A;Stratford S;Vaught JD;Vrkljan M;Walker JJ;Watrobka M;Waugh S;Weiss A;Wilcox SK;Wolfson A;Wolk SK;Zhang C;Zichi D
通讯作者:
Zichi D
影响因子:
25
作者:
Mostafavi S;Gaiteri C;Sullivan SE;White CC;Tasaki S;Xu J;Taga M;Klein HU;Patrick E;Komashko V;McCabe C;Smith R;Bradshaw EM;Root DE;Regev A;Yu L;Chibnik LB;Schneider JA;Young-Pearse TL;Bennett DA;De Jager PL
通讯作者:
De Jager PL
DOI:
10.3233/jad-200948
发表时间:
2021
期刊:
Journal of Alzheimer's disease : JAD
影响因子:
--
作者:
Birkenbihl C;Westwood S;Shi L;Nevado-Holgado A;Westman E;Lovestone S;AddNeuroMed Consortium;Hofmann-Apitius M
通讯作者:
Hofmann-Apitius M
影响因子:
25
作者:
Johnson ECB;Carter EK;Dammer EB;Duong DM;Gerasimov ES;Liu Y;Liu J;Betarbet R;Ping L;Yin L;Serrano GE;Beach TG;Peng J;De Jager PL;Haroutunian V;Zhang B;Gaiteri C;Bennett DA;Gearing M;Wingo TS;Wingo AP;Lah JJ;Levey AI;Seyfried NT
通讯作者:
Seyfried NT
影响因子:
16.2
作者:
Bai, Bing;Wang, Xusheng;Peng, Junmin
通讯作者:
Peng, Junmin